GLP-1 Eye Effects Raise Questions - Takeaways - MDSpire

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

  • By

  • Kerri Miller

  • March 24, 2026

  • 2 min

Share

  • 1

    Semaglutide is associated with ischaemic optic neuropathy, with higher reporting odds in males and those using obesity-dose formulations.

  • 2

    Observational studies suggest GLP-1 receptor agonists may reduce risks of nonexudative age-related macular degeneration and noninfectious uveitis.

  • 3

    A 3-year study found a twofold increase in neovascular age-related macular degeneration among diabetes patients using GLP-1 RAs.

  • 4

    Pharmacovigilance data indicate the need for further study on the ocular effects of GLP-1 RAs, especially with increasing usage.

  • 5

    Experts recommend screening for diabetic retinopathy before initiating GLP-1 RAs and reporting adverse events through the yellow card system.

Original Source(s)

GLP-1 Eye Effects Raise Questions

  • by Kerri Miller

  • March 24, 2026

Related Content

Combination Therapy May Increase Lesion Closure in PCV

The combination of photodynamic therapy and intravitreal  aflibercept did not improve 1-year visual acuity outcomes compared with aflibercept monotherapy.

Distinctive vascular changes in the retina and choroid linked to retrograde flow in the ophthalmic artery due to chronic total occlusion of the carotid artery

AI Boosts Diabetic Eye Care Access

Recent study highlights how integrated AI-assisted DR screening in primary care clinics can improve access and decrease disparity

  • May 5, 2026

  • 3 min